ADORE clinical trial open to recruitment of people with MND in the UK
02 November 2022
02 November 2022
The ADORE (ALS Deceleration with ORal Edaravone) clinical trial is a phase 3 clinical trial of the investigational drug FNP122. This is an oral formulation of the drug edaravone, which is licensed for the treatment of MND in some countries including the US and Canada (it is not licensed in the UK).
FNP122 can help prevent oxidative stress, which is thought to contribute to nerve cell death in MND. By decreasing oxidative stress, edaravone could potentially slow the progression of MND.
ADORE is a double-blind, randomised, placebo-controlled trial:
Both FNP122 and the placebo can be dissolved in water and taken as a drink. This formulation is often easier for people with MND to swallow and reduces the need for visits to hospital to receive an intravenous injection. At the end of the trial, all participants will be offered the chance to enter the open-label extension (OLE), in which they will receive daily FNP122, regardless of whether they received the active drug or the placebo in the initial stage of the trial.
How can you participate in the ADORE trial?
The ADORE trial is currently recruiting at the following sites in the UK:
The trial will run for up to 48 weeks (approximately 11 months). During this period, you will need to visit the research centre approximately 9 times, and you will also be contacted by telephone 7 times.
The main criteria* to participate in the ADORE trial are:
*This list is not exhaustive, and you should speak to your consultant about your suitability to participate in this trial if you are interested. Alternatively, contact the TRICALS consortium at firstname.lastname@example.org.